Federal Register / Vol. 72, No. 230 / Friday, November 30, 2007 / Notices 67743 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: November 26, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–5882 Filed 11–29–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, ZRG RUS F 

51 Nephrology Applications. 

Date: December 10–11, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Ryan G. Morris, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4205, 

MSC 7814, Bethesda, MD 20892, 301–435–

1501, morrisr@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: November 19, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–5877 Filed 11–29–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Development of FDA 

Approved HIV Resistance Diagnosis 

Kit 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health (NIH), Department 

of Health and Human Services, is 

contemplating the grant of an exclusive 

license to practice the invention 

embodied in U.S. Patent No. 5,714,313, 

issued February 03, 1998, entitled 

‘‘Simple Method For Detecting 

Inhibitors Of Retroviral Replication’’

(HHS Ref. E–054–1991/1–US–01) 

(Inventors: David Garfinkel, Joan Curcio, 

Dwight Nissley and Jeffrey Strathern) 

(NCI), to AmiKana.BioLogics (Hereafter 

AmiKana), having a place of business in 

France. The patent rights in these 

inventions have been assigned to the 

United States of America. 

DATES: Only written comments and/or 

application for a license, which are 

received by the NIH Office of 

Technology Transfer on or before 

January 29, 2008 will be considered. 

ADDRESSES: Requests for a copy of the 

patent application, inquiries, comments 

and other materials relating to the 

contemplated license should be directed 

to: Sally Hu, Ph.D., M.B.A., Office of 

Technology Transfer, National Institutes 

of Health, 6011 Executive Boulevard, 

Suite 325, Rockville, MD 20852–3804; 

E-mail: hus@od.nih.gov; Telephone: 

(301) 435–5606; Facsimile: (301) 402–

0220. 

SUPPLEMENTARY INFORMATION: The 

subject technology discloses a DNA 

vector comprised of a selectable marker 

gene inserted into a retrotransposon for 

use in identifying and selecting cells in 

which retrotransposition has occurred. 

This novel method uses a 

retrotransposon comprised of a 

retroviral reverse transcriptase/RNAse H 

gene domain, which creates a unique 

restriction enzyme site wherever reverse 

transcription occurs. This novel system 

offers a means of identifying 

compounds or agents that can inhibit 

retrotransposition or retroviral 

replication. Previous methods 

developed to detect retrotransposition 

have not been able to accurately identify 

DNA in which reverse transcription has 

occurred. Certain types of 

retrotransposition are similar to 

retroviral replication. Thus, this method 

is applicable to identifying antiretroviral 

compounds as well as inhibitors of 

retrotransposition. 

The field of use may be limited to the 

development of FDA approved HIV 

resistance diagnosis kit through the 

combination of the subject technology 

and AmiKana’s proprietary yeast based 

HIV protease phenotyping procedure 

(Patent Publication No. 

WO2006000693). 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless, 

within 60 days from the date of this 

published Notice, NIH receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR 404.7. 

Properly filed competing applications 

for a license filed in response to this 

notice will be treated as objections to 

the contemplated license. Comments 

and objections submitted in response to 

this notice will not be made available 

for public inspection, and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: November 19, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–23191 Filed 11–29–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket No. FEMA–2007–0013] 

National Advisory Council 

AGENCY: Federal Emergency 

Management Agency, DHS. 

ACTION: Notice of teleconference 

meeting. 

SUMMARY: The National Advisory 

Council (NAC) will be holding a 

teleconference meeting for purposes of 

discussing governance and standard 

operating procedures. The 

teleconference meeting will be open to 

the public. 

DATES: Meeting Date: Tuesday, 

December 18, 2007, 1 p.m.–2 p.m. e.s.t. 

Comment Date: Written comments must 

be received by December 14, 2007. 


rwilkins on PROD1PC63 with NOTICES